Advanced Rheumatology Course (ARC): All Activities

ARC is a series of 19 activities that provides foundational knowledge and sets up new rheumatology professionals for clinical practice success.

$239900

Product Code: ADV-ALL-EXP25

Pricing Info: Member: $1999
Non-Member: $2399

Activity Format: Self-Paced

Topic(s): Basic & Clinical Sciences, Infections & Related Arthritides, Lupus, Rheumatoid Arthritis

Start Date: Wednesday, August 16, 2023, 12:00 AM

End Date: Saturday, August 15, 2026, 11:55 PM

Credit: CME, Participation

Target Audience: Advanced Practice Nurses, Counselors, Nurses, Occupational Therapists, Pharmacists, Practice Administrators, Primary Care Providers, Physical Therapists, Physician Assistants, Researchers, Residents

Curriculum: Advanced Rheumatology Course

CME: 25.00

Description

The Advanced Rheumatology Course is a 19-activity series for advanced practice providers and other professionals who need a deeper dive into rheumatology. The series covers how to assess and manage patients with rheumatic disease, develop strategies to integrate NP/PAs into rheumatology practice, and improve access to care for patients. The advanced information will help experienced practice providers function well in rheumatology and foster inter-professional collaboration.

Advanced Rheumatology Course Series

This activity includes all activities in the series.

Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP.

Target Audience

Advanced practice nurses and physician assistants. Fellows-in training, residents, students, primary care providers, physical therapists, and researchers may also benefit.

Learning Objectives

Upon completion of this activity, participants should be able to:

Assess and manage patients with rheumatic diseases as part of an interprofessional collaborative care team
Develop strategies to integrate the nurse practitioner and physician assistant into a collaborative rheumatology practice
Assist in decreasing wait times for appointments and improve access to care for patients with rheumatic disease by improving the competence and performance of nurse practitioners and physician assistants in a collaborative rheumatology practice

CE & MOC Information

CME

ACCME Accreditation Statement

The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Designation Statement

The American College of Rheumatology designates this enduring material for a maximum of 25.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

See the ACR's CME Mission Statement. For more information, download the AMA PRA Booklet.

CME credit must be claimed by August 14, 2026, at 11:59 PM ET.

Financial Relationships Disclosures

ACR Disclosure Statement

It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at http://accme.org .

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.

Nature of Financial Relationships

All individuals involved or able to influence the content of this accredited activity have disclosed to the editorial team and audience any/all financial or other relationship(s) including, but not limited to:

Advisor or review panel member
Consultant
Employee
Officer or Board Member
Grant/research support
Speaker/honoraria includes speaker’s bureau, symposia, and expert witness
Independent contractor
Executive role and/or ownership interest
Royalties and/or patent beneficiary
Intellectual property/patents
Stock options or bond holdings in a for-profit corporation or self-directed pension plan
Private investigator
Expert witness
Equity interest
Other: specify details

None: Has no relevant financial relationship(s) with ineligible companies to disclose.

All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated.

Faculty

ARC01: Musculoskeletal Structure And Function And Inflammation And Immunity

Authors/Planners

Kenneth S. O’Rourke, MD - No relevant financial relationships to disclose
Rachel M. Wolfe, MD - No relevant financial relationships to disclose

Editors and Reviewers

Daniel Schaffer, MD – No relevant financial relationships to disclose
Anneke Smith – No relevant financial relationships to disclose
Ben Smith, DMSc, PA-C, DFAAPA – No relevant financial relationships to disclose

ARC02: Framework for Clinical Decision Making in Rheumatology

Author

Megan Lockwood, MD - No relevant financial relationships to disclose

Editors and Reviewers

Jennifer Grossman, MD - No relevant financial relationships to disclose
Anneke Smith – No relevant financial relationships to disclose
Sonam Kiwalkar, MD – No relevant financial relationships to disclose

ARC03: Laboratory Evaluation of Rheumatic Disease

Author

Beth Jonas, MD – No relevant financial relationships to disclose

Editors and Reviewers

Laurie Hughell, MPH, PA-C - No relevant financial relationships to disclose
Anneke Smith – No relevant financial relationships to disclose
Ben Smith, DMSc, PA-C, DFAAPA – No relevant financial relationships to disclose

ARC04: Imaging of Arthritis

Author

Beth Jonas, MD – No relevant financial relationships to disclose

Editors and Reviewers

Laurie Hughell, MPH, PA-C - No relevant financial relationships to disclose
Anneke Smith – No relevant financial relationships to disclose
Ben Smith, DMSc, PA-C, DFAAPA – No relevant financial relationships to disclose

ARC05: Coding And Practice Issues

Author

J. Eugene Huffstutter, MD - No relevant financial relationships to disclose

Editors and Reviewers

Fredrica Smith, MD - No relevant financial relationships to disclose
Julie Lahti - No relevant financial relationships to disclose
Ben Smith, DMSc, PA-C, DFAAPA - No relevant financial relationships to disclose

ARC06: Therapeutic Interventions And Resources

Authors/Planners

Donna Everix, MPH, PT - No relevant financial relationships to disclose
Jennifer Trizuto, DPT - No relevant financial relationships to disclose

Editors and Reviewers

Marie Westby, PT, PhD - Janssen Canada⁵; Ended 2020; Pfizer⁵; Ended 2020
Julie Lahti - No relevant financial relationships to disclose
Ben Smith, DMSc, PA-C, DFAAPA - No relevant financial relationships to disclose

ARC07: Osteoarthritis

Authors/Planners

Abhijeet Danve, MD – AbbVie/Abbott¹; Novartis¹
Yuliya Afinogenova, MD - No relevant financial relationships to disclose
Swetha Alexander, MD - No relevant financial relationships to disclose

Editors and Reviewers

Janeth Yinh, MD – No relevant financial relationships to disclose
Anneke Smith – No relevant financial relationships to disclose
Sonam Kiwalkar, MD – No relevant financial relationships to disclose

ARC08: RA and Seronegative Inflammatory Arthropathies

Author

Gregory C. Gardner, MD, MACP – No relevant financial relationships to disclose

Editors and Reviewers

Sheila Arvikar, MD – No relevant financial relationships to disclose
Julie Lahti - No relevant financial relationships to disclose
Sonam Kiwalkar, MD – No relevant financial relationships to disclose

ARC09: Systemic Lupus Erythematosus

Authors/Planners

Mary Chester Wasko, MD, AbbVie/Abbott²; AstraZeneca²; EMD Serono²; GlaxoSmithKlein²; HGS²; Roche²
Joanna Marco, MD – No relevant financial relationships to disclose

Editors and Reviewers

Paul Monach, MD, PhD – Celgene¹; Chemocentryx⁶; Kiniksa¹⁶
Anneke Smith – No relevant financial relationships to disclose
Marcy Bolster, MD – AbbVie²; American Board of Internal Medicine: Chair, ABIM Rheumatology Board⁶; Amgen²; Corbus Pharmaceuticals²; Cumberland²; Genentech²; Gilead Sciences⁵; Johnson & Johnson¹; Pfizer²

ARC10: Systemic Inflammatory Conditions

Authors/Planners

Jason Kolfenbach, MD: ChemoCentryx⁵
Tara Skorupa, MD: No relevant financial relationships to disclose

Editors and Reviewers

Zsuzsanna McMahon – No relevant financial relationships to disclose
Marcy Bolster, MD – AbbVie²; American Board of Internal Medicine: Chair, ABIM Rheumatology Board⁶; Amgen²; Corbus Pharmaceuticals²; Cumberland²; Genentech²; Gilead Sciences⁵; Johnson & Johnson¹; Pfizer²
Julie Lahti – No relevant financial relationships to disclose

ARC11: Vasculitis, Arteritis and PMR

Authors/Planners

Anisha Dua, MD - AbbVie/Abbott^{5, 8}; ChemoCentryx⁵; Novartis⁵
Josh Waytz, MD – No relevant financial relationships to disclose

Editors and Reviewers

Paul Monach, MD, PhD – Celgene¹; Chemocentryx⁶; Kiniksa
Anneke Smith – No relevant financial relationships to disclose
Marcy Bolster, MD – AbbVie²; American Board of Internal Medicine: Chair, ABIM Rheumatology Board⁶; Amgen²; Corbus Pharmaceuticals²; Cumberland²; Genentech²; Gilead Sciences⁵; Johnson & Johnson¹; Pfizer²

ARC12: Crystal-Induced Arthropathies

Author

Puja Khanna, MD – DYVE²; Horizon^1,2,5; Select^1,2

Editors and Reviewers

Chio Yokose, MD – No relevant financial relationships to disclose
Anneke Smith – No relevant financial relationships to disclose
Sonam Kiwalkar, MD – No relevant financial relationships to disclose

ARC13: Pain Syndromes

Author

Andrew Heisler, MD – No relevant financial relationships to disclose

Editors and Reviewers

Sonam Kiwalkar, MD – No relevant financial relationships to disclose
Christine Stamatos, DNP – No relevant financial relationships to disclose
Julie Lahti – No relevant financial relationships to disclose

ARC14: Spondyloarthritis

Authors/Planners

Atul Deodhar, MD - AbbVie/Abbott⁵²⁸; Amgen⁵²⁸; BMS⁵²⁸; Boheringer Ingelheim⁵²⁸; Celgene⁵²⁸; Gilead⁵²⁸; Glapagos⁵²⁸; Janssen⁵²⁸; Lilly⁵²⁸; Novartis⁵²⁸; Pfizer⁵²⁸; UCB⁵²⁸
Anand Kumthekar, MD – No relevant financial relationships to disclose

Editors and Reviewers

Abhijeet Danve, MD – AbbVie/Abbott¹; Novartis¹
Anneke Smith – No relevant financial relationships to disclose
Sonam Kiwalkar, MD – No relevant financial relationships to disclose

ARC15: Infection-Related Arthritis

Authors/Planners

Robert A. Kalish, MD – No relevant financial relationships to disclose
Janet Hong, MD – No relevant financial relationships to disclose
Frank Scangarello, MD, PhD – No relevant financial relationships to disclose

Editors and Reviewers

Michael Battistone, MD – American Board of Internal Medicine Rheumatology Exam Committee⁶: Advisor or Review Panel member
Anneke Smith – No relevant financial relationships to disclose
Marcy Bolster, MD – AbbVie²; American Board of Internal Medicine: Chair, ABIM Rheumatology Board⁶; Amgen²; Corbus Pharmaceuticals²; Cumberland²; Genentech²; Gilead Sciences⁵; Johnson & Johnson¹; Pfizer²

ARC16: Osteoporosis And Other Metabolic Bone Disorders

Author

Sarah Keller, MD – No relevant financial relationships to disclose

Editors and Reviewers

Alfred Denio, MD – Abbvie⁸; Bristol-Myers Squibb⁵
Marcy Bolster, MD – AbbVie²; American Board of Internal Medicine: Chair, ABIM Rheumatology Board⁶; Amgen²; Corbus Pharmaceuticals²; Cumberland²; Genentech²; Gilead Sciences⁵; Johnson & Johnson¹; Pfizer²
Julie Lahti – No relevant financial relationships to disclose

ARC17: Comprehensive Overview of Juvenile Idiopathic Arthritis (JIA)

Author

Betsy Roth-Wojcicki, RN, MS, CPNP-PC - No relevant financial relationships to disclose

Editors and Reviewers

Heather Benham, APRN, CPNP, DNP, RhMSUS – No relevant financial relationships to disclose
Anneke Smith - No relevant financial relationships to disclose
Ben Smith, DMSc, PA-C, DFAAPA – No relevant financial relationships to disclose

ARC18: Comprehensive Overview of Pediatric Connective Tissue Diseases (CTD)

Author

Heather Benham, DNP, APRN, CPNP-PC, RhMSUS – No relevant financial relationships to disclose

Editors and Reviewers

Natasha Ruth, MD, MS – No relevant financial relationships to disclose
Marcy Bolster, MD – AbbVie²; American Board of Internal Medicine: Chair, ABIM Rheumatology Board⁶; Amgen²; Corbus Pharmaceuticals²; Cumberland²; Genentech²; Gilead Sciences⁵; Johnson & Johnson¹; Pfizer²
Julie Lahti – No relevant financial relationships to disclose

ARC19: Pediatric Noninflammatory Musculoskeletal Pain

Author

Bethany A. Marston, MD – No relevant financial relationships to disclose

Editors and Reviewers

Susan Shenoi, MS, MBBS, RhMSUS – Pfizer⁵
Julie Lahti - No relevant financial relationships to disclose
Sonam Kiwalkar, MD – No relevant financial relationships to disclose

*All of the relevant financial relationships listed for these individuals have been mitigated.

Acknowledgement of Commercial Support

The project was supported by Grant number 1 NU58DP006908-03-00 – Component A; Developing and Disseminating Programs to Build Sustainable Lupus Awareness, Knowledge, Skills and Partnerships. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Health and Human Services, Centers for Disease Control and Prevention.

Educational Activity Policies

See ACR educational activity policies, including the online enduring activity refund policy.

Activities

ARC01: Musculoskeletal Structure And Function And Inflammation And Immunity

ARC02: Framework for Clinical Decision Making in Rheumatology

ARC03: Laboratory Evaluation of Rheumatic Disease

ARC04: Imaging of Arthritis

Learn about different imaging modalities to aid in diagnosing rheumatic disease and making informed decisions regarding the most suitable treatments for patients.

ARC05: Coding And Practice Issues

ARC06: Therapeutic Interventions And Resources

ARC07: Osteoarthritis

Learn how osteoarthritis adversely affects mobility, significantly contributes to disability rates, and imposes substantial a financial burden on society.

ARC08: RA and Seronegative Inflammatory Arthropathies

ARC09: Systemic Lupus Erythematosus

Explore the various manifestations of lupus, effective methods for diagnosing the condition, and optimal approaches for managing patients with lupus.

ARC10: Systemic Inflammatory Conditions

ARC11: Vasculitis, Arteritis and PMR

ARC12: Crystal-induced Arthropathies

ARC13: Pain Syndromes

Increase your knowledge on pain syndromes for your patients with rheumatic disease and learn about delivering optimal patient care.

ARC14: Spondyloarthritis

ARC15: Infection-Related Arthritis

ARC16: Osteoporosis And Other Metabolic Bone Disorders

ACTIVITY OVERVIEW The Advanced Rheumatology Course is a19-activity series for advanced practice providers and other professionals who need a deeper dive into rheumatology. The series covers how to assess and manage patients with rheumatic disease, develop strategies to integrate NP/PAs into rheumatology practice, and improve access to care for patients. The advanced information will help experienced practice providers function well in rheumatology and foster inter-professional collaboration. This activity explores osteoporosis and other metabolic bone disorders, including how to care for patients with these conditions. ADVANCED RHEUMATOLOGY COURSE SERIES This activity is part of a series. See the other activities in the series below. * Advanced Rheumatology Course: All Activities * ARC01: Musculoskeletal Structure And Function And Inflammation And Immunity * ARC02: Framework for Clinical Decision Making in Rheumatology * ARC03: Laboratory Evaluation of Rheumatic Disease * ARC04: Imaging of Arthritis * ARC05: Coding and Practice Issues * ARC06: Therapeutic Interventions And Resources * ARC07: Osteoarthritis * ARC08: RA and Seronegative Inflammatory Arthropathies * ARC09: Systemic Lupus Erythematosus * ARC010: Systemic Inflammatory Conditions: Inflammatory Myopathy * ARC11: Vasculitis, Arteritis and PMR * ARC12: Crystal-Induced Arthropathies * ARC13: Pain Syndromes * ARC14: Spondyloarthritis * ARC15: Infection-Related Arthritis * ARC16: Osteoporosis And Other Metabolic Bone Disorders * ARC17: Comprehensive Overview of Juvenile Idiopathic Arthritis (JIA) * ARC18:Comprehensive Overview of Pediatric Connective Tissue Diseases (CTD) * ARC19: Pediatric Noninflammatory Musculoskeletal Pain Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP. TARGET AUDIENCE Advanced practice nurses and physician assistants. Fellows-in training, residents, students, primary care providers, physical therapists, and researchers may also benefit. LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: * Recognize the risk factors for fracture in women with postmenopausal osteoporosis * Interpret bone density reports and demonstrate how to use bone density studies for clinical decision making * Describe the important nutritional components of bone health including calcium and Vitamin D and the consequences of deficiencies * Formulate basic treatment plans for patients with postmenopausal osteoporosis * Design a clinical profile for men at risk for osteoporosis and discuss a metabolic workup for men with osteoporosis * Contrast the pathophysiology of glucocorticoid induced osteoporosis (GIOP) with postmenopausal osteoporosis and formulates treatment plans for patients on glucocorticoids therapy * Evaluate the epidemiology, pathophysiology, clinical and radiological aspects, and a treatment plan for Pagets disease CE & MOC INFORMATION ACCME ACCREDITATION STATEMENT The American College of Rheumatology (ACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AMA DESIGNATION STATEMENT The American College of Rheumatology designates this enduring material for a maximum of 2.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. See the ACRs CME Mission Statement. For more information, download the AMA PRA Booklet. _CME credit must be claimed by August 14, 2026, at 11:59 PM ET._ FINANCIAL RELATIONSHIP DISCLOSURES ACR DISCLOSURE STATEMENT It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity. NATURE OF FINANCIAL RELATIONSHIPS All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to: * Advisor or review panel member * Consultant * Employee * Officer or Board Member * Grant/research support * Speaker/honoraria includes speaker’s bureau, symposia, and expert witness * Independent contractor * Executive role and/or ownership interest * Royalties and/or patent beneficiary * Intellectual property/patents * Stock options or bond holdings in a for-profit corporation or self-directed pension plan * Private investigator * Expert witness * Equity interest * Other: _specify details_ None: Has no relevant financial relationship(s) with ineligible companies to disclose. All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. AUTHOR * Sarah Keller, MD – No relevant financial relationships to disclose EDITORS AND REVIEWERS * Alfred Denio, MD – Abbvie8; Bristol-Myers Squibb5 * Marcy Bolster, MD – AbbVie2; American Board of Internal Medicine: Chair, ABIM Rheumatology Board6; Amgen2; Corbus Pharmaceuticals2; Cumberland2; Genentech2; Gilead Sciences5; Johnson & Johnson1; Pfizer2 * Julie Lahti – No relevant financial relationships to disclose ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT The project was supported by Grant number 1 NU58DP006908-03-00 – Component A; Developing and Disseminating Programs to Build Sustainable Lupus Awareness, Knowledge, Skills and Partnerships. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Health and Human Services, Centers for Disease Control and Prevention. EDUCATIONAL ACTIVITY POLICIES See ACR educational activity policies, including the online enduring activity refund policy.